Last reviewed · How we verify

BeyondSpring Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

BeyondSpring Pharmaceuticals Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Docetaxel (D) Docetaxel (D) marketed Taxane; microtubule stabilizer β-tubulin Oncology
Docetaxel + Plinabulin (DP) Docetaxel + Plinabulin (DP) phase 3 Taxane + microtubule-disrupting agent combination Microtubules (β-tubulin); immune cell migration pathways Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Aravive, Inc. · 1 shared drug class
  3. Athenex, Inc. · 1 shared drug class
  4. Barts & The London NHS Trust · 1 shared drug class
  5. Bio-Thera Solutions · 1 shared drug class
  6. Dai, Guanghai · 1 shared drug class
  7. Fujian Medical University · 1 shared drug class
  8. Guangzhou Double Bioproducts Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BeyondSpring Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). BeyondSpring Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beyondspring-pharmaceuticals-inc. Accessed 2026-06-10.

Related